CellCentric Secures £90m in Series C to Advance Cancer Treatment
Deal News | May 19, 2025 | Business Cloud
CellCentric, a UK-based MedTech company, has successfully secured £90 million in its Series C funding round to further develop its oral treatment for multiple myeloma, known as inobrodib. Led by RA Capital Management and new investor Forbion, the investment also saw contributions from Avego Bioscience Capital and BrightEdge, the American Cancer Society's venture capital arm. Despite advancements in treating multiple myeloma, many patients either are ineligible for current treatments or develop resistance, leaving a significant unmet need in the market. Inobrodib, with its novel mechanism of action and favorable safety profile, positions itself as a promising therapeutic option. CellCentric's CEO, Will West, expresses confidence in the investment's impact on the company's growth amid the challenging market environment. Notable past investments include $35 million from RA Capital and $25 million from Pfizer. The company has also expanded its global presence with a new office in Burlington, Massachusetts, to bolster its international team.
Sectors
- MedTech
- Venture Capital
Geography
- United Kingdom – CellCentric is based in Cambridge, UK, where it is developing its treatment.
- United States – The investment includes RA Capital Management, Forbion's new operations in the US, and the opening of CellCentric's office in Burlington, Massachusetts.
Industry
- MedTech – The article focuses on CellCentric, a MedTech company developing a novel treatment for multiple myeloma.
- Venture Capital – The funding round was co-led by venture capital firms, highlighting the venture capital industry's role in financing innovative healthcare solutions.
Financials
- £90 million – The total sum raised in CellCentric's Series C funding round to support the development of inobrodib.
- $35 million – Previous investment amount from RA Capital last year.
- $25 million – Previous strategic investment from Pfizer.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| CellCentric | Target Company | Company | A MedTech company focused on developing treatments for multiple myeloma. |
| RA Capital Management | Co-Lead Investor | Company | A life sciences investment firm that co-led the Series C funding for CellCentric. |
| Forbion | Co-Lead Investor | Company | A European life sciences venture capital firm and new investor in CellCentric. |
| Avego Bioscience Capital | Investor | Company | A participant in the funding round supporting CellCentric. |
| BrightEdge | Investor | Company | The venture capital and impact investment arm of the American Cancer Society, participating in the funding round. |
| Will West | CEO | People | CEO of CellCentric, leading the company's strategic and operational management. |
| Jasper Bos | Board Member | People | General partner at Forbion and newly joined board member of CellCentric. |